Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
暂无分享,去创建一个
[1] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Kantarjian,et al. Granulocyte–colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase chronic myelogenous leukemia , 2004, Cancer.
[3] U. Demirci,et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors , 2010, Medical oncology.
[4] K. Harrold,et al. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[5] P. Thall,et al. Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate , 2007, Clinical Cancer Research.
[6] D. Alexandrescu,et al. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. , 2008, Dermatology online journal.
[7] J. Desai,et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) , 2005 .
[8] K. Jimbow,et al. Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R , 1995, Melanoma research.
[9] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[10] S. Silver,et al. Heart Failure , 1937, The New England journal of medicine.
[11] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[12] T. Links,et al. Imatinib induces hypothyroidism in patients receiving levothyroxine , 2005, Clinical pharmacology and therapeutics.
[13] G. Demetri,et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Joensuu. Sunitinib for imatinib-resistant GIST , 2006, The Lancet.
[15] J. Desai,et al. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.
[16] H. Joensuu,et al. Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.
[17] B. Rini,et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. , 2007, Journal of the National Cancer Institute.
[18] C. Heldin,et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] Jin-Hwang Liu,et al. Stevens–Johnson syndrome after treatment with STI571: a case report , 2002, British journal of haematology.
[20] F. Dawkins,et al. Hypopigmentation in an African patient treated with imatinib mesylate: a case report. , 2003, Journal of the National Medical Association.
[21] M. Halushka,et al. Heart failure associated with sunitinib malate , 2008, Cancer.
[22] J. Verweij,et al. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.
[23] P. Marynen,et al. Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.
[24] Sigrid Stroobants,et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.
[25] H. Joensuu,et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] Pingfu Fu,et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Seeber,et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function , 2002, Anti-cancer drugs.
[28] A. Templeton,et al. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] G. Demetri,et al. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. , 2005, Clinical journal of oncology nursing.
[30] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[32] M. Tulliez,et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. , 2003, Journal of the American Academy of Dermatology.
[33] J. Blay,et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. , 2007, European journal of cancer.
[34] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[35] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Y. Meng,et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.
[37] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[39] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] Hiroaki Nakamura,et al. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c‐Fms signals , 2009, International journal of cancer.
[42] J. Plana,et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate , 2009, Cancer.
[43] M. Hotopf,et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. , 2008, Journal of the National Cancer Institute.
[44] A. Maia,et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. , 2008, European journal of endocrinology.
[45] J. Verweij,et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] S. Kudoh,et al. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate , 2006, Leukemia.
[47] F. Mandelli,et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[49] N. Pryer,et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.
[50] E. Bonora,et al. Imatinib and regression of type 2 diabetes. , 2005, The New England journal of medicine.
[51] G. Schwarzer,et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. , 2006, Journal of the National Cancer Institute.
[52] R. Benjamin,et al. A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas , 2003, Cancer.
[53] Alain Spatz,et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.
[54] S. Corsello,et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy , 2009, Nature Reviews Clinical Oncology.
[55] J. Desai,et al. Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management * , 2007 .
[56] Vivek Roy,et al. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer , 2008 .
[57] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[58] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[59] B. Gilchrest,et al. SCF/c‐kit signaling is required for cyclic regeneration of the hair pigmentation unit , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] C. Tomoda,et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. , 2007, Thyroid : official journal of the American Thyroid Association.
[61] M. Marples,et al. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[62] H. Worthington,et al. Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer). , 2000, The Cochrane database of systematic reviews.
[63] J. Ford,et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] J. Blay,et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.
[65] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[66] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[67] M. Zwahlen,et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.
[68] P. Hinds,et al. NCCN Practice Guidelines for Cancer-Related Fatigue. , 2000, Oncology.
[69] M. Schlemmer,et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] F. Kabbinavar,et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period , 2008, Cancer Chemotherapy and Pharmacology.
[72] G. Bjarnason,et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[73] D. Sica. Angiogenesis inhibitors and hypertension: an emerging issue. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Glenn Heller,et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. , 2006, The New England journal of medicine.
[75] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[76] S. Fitter,et al. Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.
[77] J. Blay,et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). , 2006, European journal of cancer.
[78] K. Arimori,et al. EFFECTS OF POMEGRANATE JUICE ON HUMAN CYTOCHROME P450 3A (CYP3A) AND CARBAMAZEPINE PHARMACOKINETICS IN RATS , 2005, Drug Metabolism and Disposition.
[79] J. Blay,et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] A. D. Van den Abbeele,et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[81] H. Wildiers,et al. Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] D. West,et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib , 2008, Supportive Care in Cancer.
[83] L. Berlin,et al. Standard of care. , 1998, AJR. American journal of roentgenology.
[84] Stefan Meyer,et al. Interventions for treating oral mucositis for patients with cancer receiving treatment. , 2010, The Cochrane database of systematic reviews.
[85] L. Mariani,et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib , 2003, The Lancet.
[86] P. Casali,et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. , 2007, The Journal of clinical endocrinology and metabolism.
[87] Jonathan D. Solomon,et al. Ocular side-effects associated with imatinib mesylate (Gleevec). , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[88] S. Oudard,et al. Home blood-pressure monitoring in patients receiving sunitinib. , 2008, The New England journal of medicine.